Intravenous dantrolene for class iii antiarrhythmic drug resistant refractory ventricular arrhythmias in patients with heart failure: final results of a phase ii study

10 May 2026 (16:30 - 17:15)
Organised by: Logo
Congress Presentation Part of: Sudden cardiac death, ventricular arrhythmias, and emerging treatment strategies Clinical HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

ESC 365 is supported by

ESC 365 is supported by